10-Q: BioLargo Inc. Reports Strong Revenue Growth in Q3 2024, Fueled by Consumer Product Sales

BioLargo, Inc. saw a significant increase in revenue during the third quarter of 2024, primarily driven by sales of its private-label pet odor control product.

Summary

• BioLargo, Inc. reported a 63% increase in revenue for the three months ended September 30, 2024, reaching $4.351 million, and an 80% increase for the nine months ended September 30, 2024, reaching $14.122 million.
• The revenue growth was primarily due to increased sales of the 'Pooph' branded pet odor control product, which accounted for 76% and 78% of the company's total revenue for the three and nine month periods, respectively.
• The company's net loss for the three months ended September 30, 2024, was $1.060 million, or $0.002 per share, and $2.615 million, or $0.005 per share for the nine months ended September 30, 2024.
• BioLargo's operating loss for the three and nine months ended September 30, 2024, was $1.061 million and $2.715 million, respectively.
• The company's cash and cash equivalents totaled $3.882 million as of September 30, 2024, with total current assets of $7.394 million and working capital of $4.194 million.
• BioLargo continues to invest in capital equipment and research and development, particularly in its battery technology and PFAS removal system.
• The company raised $2.858 million from financing activities during the nine months ended September 30, 2024, including sales of stock, warrant exercises, and option exercises.
• BioLargo acknowledges that it will continue to need further investment capital to fund its business plans and new technologies, raising substantial doubt about its ability to continue as a going concern without additional revenue, financing, or asset conversion.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth and progress in technology development, the company's financial position and going concern status raise significant concerns. The reliance on a single product line and the long sales cycles for some technologies also add to the uncertainty.

Positives

• Significant revenue growth driven by the success of the 'Pooph' branded product.
• Net losses decreased compared to the same periods in the previous year.
• The company has secured new contracts for its engineering services, providing a stable revenue stream.
• BioLargo is actively developing and commercializing innovative technologies in water treatment and battery storage.
• The company has a strong pipeline of potential projects for its PFAS treatment technology.
• Clyra Medical is preparing for the national rollout of its Bioclynse product, having invested in manufacturing equipment and appointed a Chief Medical Officer.

Negatives

• The company continues to operate at a net loss.
• BioLargo's financial statements raise substantial doubt about its ability to continue as a going concern without additional revenue, financing, or asset conversion.
• The company is heavily reliant on a single product line ('Pooph') for the majority of its revenue.
• The sales cycle for municipal and industrial water treatment equipment is long, which may delay revenue generation from these products.
• BLEST's cost of revenues increased significantly in the current period due to increased costs on fixed fee contracts and work on the AEC project.
• Clyra Medical has not yet begun commercial sales of its Bioclynse product and continues to incur significant expenses.

Risks

• The company's reliance on a single product line ('Pooph') makes it vulnerable to fluctuations in demand or changes in the market.
• BioLargo's ability to continue as a going concern is dependent on its ability to increase revenues, generate cash from operations, secure additional financing, or convert assets into cash.
• The long sales cycle for municipal and industrial water treatment equipment may delay revenue generation.
• The company's internal controls have a material weakness, which could affect the reliability of its financial reporting.
• The company's engineering subsidiary, BLEST, is facing challenges in managing quality, timely performance, and access to qualified staff due to increasing demand.
• The company's battery technology is still in the development phase and may not achieve commercial success.
• The company's joint venture in South Korea has struggled to gain a foothold and its future success is uncertain.

Future Outlook

BioLargo anticipates needing further investment capital to fund its business plans and new technologies. The company is focused on commercializing its technologies and securing partnerships to expand its market reach. The company is also working to address its material weakness in internal controls.

Management Comments

• Management believes ONM's industrial odor control product, CupriDyne Clean, is the number-one performing industrial odor-control product in the market.
• Management believes Bioclynse outperforms competing products as it has proven performance in biofilm disruption and inhibition, is non-toxic and non-cytotoxic, is non-sensitizing to tissue, and unlike competing products, does not need to be rinsed and/or removed from a surgical cavity.
• Management believes the AEC is scalable to small portable commercial units as well as very large commercial operations.
• Management believes Cellinity batteries will have features that far surpass comparable lithium-ion batteries.

Industry Context

The report highlights BioLargo's focus on addressing environmental challenges such as PFAS contamination and water pollution, which are significant concerns in the cleantech industry. The company's development of innovative technologies like the AEC and Cellinity battery positions it to capitalize on the growing demand for sustainable solutions. The report also notes the impact of new EPA regulations on the market for PFAS treatment technologies.

Comparison to Industry Standards

• BioLargo's AEC technology is positioned as a more cost-effective and efficient alternative to traditional PFAS removal methods like carbon filtration, ion exchange, and reverse osmosis, which are commonly used in the industry.
• The Cellinity battery is being developed as a safer, longer-lasting, and more environmentally friendly alternative to lithium-ion batteries, which are the dominant technology in the energy storage market.
• The Bioclynse wound irrigation solution is presented as a superior product compared to existing solutions due to its performance in biofilm disruption and inhibition, non-toxicity, and non-cytotoxicity.
• The company's AROS water reuse technology is being marketed as a minimal liquid discharge solution, which is a growing trend in the industrial water treatment sector.
• The AOS technology is being positioned as a more energy-efficient and effective solution for removing micropollutants compared to existing technologies like UV, electro-chlorination, and ozonation.

Management Changes

Stakeholder Impact

• Shareholders: The company's financial position and going concern status raise concerns for shareholders, but the revenue growth and technology development may offer potential for future returns.
• Employees: The company's growth and development activities may provide opportunities for employees, but the financial uncertainty could also create instability.
• Customers: The company's innovative technologies may offer solutions to environmental and health challenges for customers.
• Suppliers: The company's growth may lead to increased demand for suppliers, but the financial uncertainty could also pose risks.
• Creditors: The company's financial position and going concern status may raise concerns for creditors.

Next Steps

• BioLargo will continue to focus on commercializing its technologies and securing partnerships to expand its market reach.
• The company will work to address its material weakness in internal controls.
• BioLargo will continue to develop and test its Cellinity battery technology.
• The company will continue to market and sell its AEC PFAS treatment system and other water treatment solutions.
• Clyra Medical will continue to prepare for the national rollout of its Bioclynse product.
• BLEST will continue to expand its engineering services and support internal BioLargo projects.

Key Dates

Keywords

BioLargo, revenue growth, pet odor control, Pooph, PFAS removal, AEC, water treatment, battery technology, Cellinity, Bioclynse, Clyra Medical, BLEST, ONM Environmental, financial results, going concern